cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bolt Biotherapeutics Inc
12 own
17 watching
Current Price
$0
$0.03
(2.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
54.61M
52-Week High
52-Week High
3.64
52-Week Low
52-Week Low
1.18
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
0.01637853
P/E Ratio
P/E Ratio
36.56666667
iconMarket Capitalization54.61M
icon52-Week High3.64
icon52-Week Low1.18
iconAverage Volume0.11M
iconDividend Yield0.01637853
iconP/E Ratio36.56666667
What does the Bolt Biotherapeutics Inc do?
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Read More
How much money does Bolt Biotherapeutics Inc make?
News & Events about Bolt Biotherapeutics Inc.
Globe Newswire
2days ago
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February...
Globe Newswire
2 months ago
REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical data on BDC-3042, a ...
Globe Newswire
8 months ago
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that ...
Frequently Asked Questions
Frequently Asked Questions
What is Bolt Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Bolt Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Bolt Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Bolt Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bolt Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Bolt Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Bolt Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bolt Biotherapeutics Inc?
plus_minus_icon
What percentage is Bolt Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bolt Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.03
(2.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00